Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax has struggled since its coronavirus vaccine reached the market after the vaccines of rivals. But the company has launched a cost-cutting plan and aims to bring a new game-changing vaccine to market in a few years.

Where Will Novavax Be in 3 Years?

Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.

Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View

Novavax, Inc. (NASDAQ:NVAX ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director, IR John Jacob - President & CEO John Trizzino - Chief Commercial Officer & Chief Business Officer Filip Dubovsky - President of Research & Development James Kelly - CFO Conference Call Participants Roger Song - Jefferies Eric Joseph - JP Morgan Brendan Smith - TD Cowen Mayank Mamtani - B. Riley Alec Stranahan - Bank of America Vernon Bernardino - H.C.

Novavax, Inc. (NVAX) Q3 2023 Earnings Call Transcript

Novavax Inc. shares NVAX, -4.09% moved slightly higher premarket on Thursday after the company reported a narrower-than-expected third quarter loss but trimmed its 2023 sales guidance.

Novavax shares rise as third quarter results top expectations

Received authorization from the U.S. FDA and approval from the European Commission for the Company's updated COVID-19 vaccine, and launched the only protein-based non-mRNA vaccine option Secured broad access to Novavax's COVID-19 vaccine in the U.S. R21/Matrix-M malaria vaccine received recommendation from WHO, resulting in initial sales of Matrix-M for launch Anticipate Phase 3 COVID-19-Influenza Combination vaccine trial to commence in 2024, with potential for accelerated approval and launch in 2026 Expect to deliver total revenue at low end of guidance range for season, when accounting for some revenue shifting into first quarter 2024 Prepared to initiate additional cost reduction program, targeting over $300 million in 2024 to align company scope and structure with future COVID-19 market opportunity Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights

COVID-19 vaccine maker Novavax on Thursday beat Wall Street estimates for third-quarter revenue, boosted by U.S. government grants to help cover the expense of clinical trials, sending its shares up nearly 4% in premarket trade.

COVID vaccine maker Novavax reports better-than-expected revenue

Novavax (NASDAQ: NVAX) stock price has been a huge disappointment among investors in the past few months. After peaking at $332 during the Covid-19 pandemic, the shares have tumbled to $7.

Novavax could become a penny stock: beware of the Wyckoff theory

Novavax shares currently trade at an extremely modest price-to-sales ratio. The company has previously raised concerns about its ability to survive as a business.

Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?

GAITHERSBURG, Md. , Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m.

Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023

American Airlines

Affirm

Disney

DraftKings

Lucid Group

Planet Fitness

While the jury's still out whether the economy and the market is headed for a soft or hard landing, as interest rates remain high, that doesn't mean you should forget about which stocks to avoid. Even as it's possible that recent fears of another downturn for stocks may prove to be an overreaction, there are particular equities that still have substantial downside risk.

7 Dangerous Stocks to Avoid No Matter What

Match Group

WeWork

Novovax Inc. NVAX shares jumped 3% after the U.S. pharma firm's new COVID vaccine gained approval in the European Union.

WeWork shares plunge on report of looming bankruptcy as Match Group stock slumps on Tinder owner's Israel warning

Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU member states to bring its updated COVID-19 vaccine to those that have requested doses through the advance purchase agreement GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the European Commission has granted approval for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.

Novavax's Updated COVID-19 Vaccine Now Approved in the EU

Pending a European Commission decision, Novavax's vaccine will be the only updated protein-based non-mRNA COVID-19 vaccine available in Europe for individuals aged 12 and older GAITHERSBURG, Md. , Oct. 31, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

BioNTech SE

Moderna

Pfizer

Novavax NVAX, -5.56% stands out as a stark reminder of the biotech sector's faltering steps in 2023. Once renowned for its Nuvaxovid COVID-19 vaccine, the Maryland-based company is now grappling with financial issues, reflecting the broader challenges that continue to plague the pharmaceutical sector this year.

Biotech stocks are in a post-pandemic slump and recovery in 2024 is questionable

Full authorization of prototype enables rapid authorization of updated Novavax COVID-19 vaccines in future GAITHERSBURG, Md. , Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has granted full marketing authorization for its prototype COVID-19 vaccine Nuvaxovid™ ▼ (NVX-CoV2373) for individuals aged 12 and older for active immunization to help prevent COVID-19.

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom

GAITHERSBURG, Md. , Oct. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Singapore's Health Sciences Authority (HSA) has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore

Novavax Inc (NASDAQ:NVAX) expressed optimism about the availability of its updated Covid-19 vaccine, now being rolled out in the U.S. The biotech name is also working with the European Medicines Agency (EMA) after the regulator delayed approval of the shot.

Novavax Maintains Covid-19 Shot Rollout Optimism

Pfizer, Moderna, and Novavax each are vying for a share of the vaccine market this fall. Big pharma company Pfizer recently updated its financial guidance for the year.

Do These 5 Words From Pfizer Mean Trouble for Novavax?

Novavax said on Monday it was "encouraged" by the broad availability of its updated COVID-19 vaccine being rolled out in the U.S., days after rival Pfizer slashed its full-year revenue forecast.

Novavax positive on updated COVID vaccine availability in US

C3.ai

Beyond Meat

Carvana

Faraday Future Intelligent Electric

Fisker Inc

Soleno Therapeutics

Upstart Holdings

VinFast Auto Ltd

Wheeler Real Estate Investment Trust

Would-be Tesla rivals VinFast and Fisker are among the most-shorted stocks. So are C3.ai and Upstart, which are big stock winners in 2023.

The 10 Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA

Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.

Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand

Hubbell

Lululemon Athletica

Manchester United

Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday.

Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move

European Union (EU) regulators have delayed the decision to give approval for Novavax's variant-tailored COVID-19 vaccine, the Financial Times said on Sunday.

EU delays approval of Novavax's revised COVID vaccine - FT

Despite seemingly good news, shares of biotechnology firm Novavax (NASDAQ: NVAX ) suffered a significant decline. Earlier Friday morning, management announced the availability of its Covid-19 vaccine at major retail pharmacies across the U.S. Unfortunately for stakeholders, the news failed to spark a positive action in NVAX stock, which slipped heavily.

Novavax (NVAX) Stock Slides Despite Vaccine Availability

Novavax said on Friday its updated COVID-19 vaccine was available across pharmacies in the United States.

News for Novavax Stock (NVAX)